{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:44:18Z","timestamp":1792651458911,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["806776"],"award-info":[{"award-number":["806776"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01152-7","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:44:35Z","timestamp":1747208675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Age-related decline in IgM responses associate with reduced opsonophagocytic activity following PCV13 vaccination"],"prefix":"10.1038","volume":"10","author":[{"given":"M.","family":"Visser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Tcherniaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bijvank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W.","family":"Pride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van Baarle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"den Hartog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Buisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"1152_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1469-0691.12461","volume":"20","author":"JJ Drijkoningen","year":"2014","unstructured":"Drijkoningen, J. J. & Rohde, G. G. Pneumococcal infection in adults: burden of disease. Clin. Microbiol. Infect. 20, 45\u201351 (2014).","journal-title":"Clin. Microbiol. Infect."},{"key":"1152_CR2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1086\/529197","volume":"46","author":"B Weinberger","year":"2008","unstructured":"Weinberger, B., Herndler-Brandstetter, D., Schwanninger, A., Weiskopf, D. & Grubeck-Loebenstein, B. Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis. 46, 1078\u20131084 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"1152_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/cix419","volume":"65","author":"AMM van Deursen","year":"2017","unstructured":"van Deursen, A. M. M. et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clin. Infect. Dis. 65, 787\u2013795 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"1152_CR4","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/cid\/civ686","volume":"61","author":"CH van Werkhoven","year":"2015","unstructured":"van Werkhoven, C. H., Huijts, S. M., Bolkenbaas, M., Grobbee, D. E. & Bonten, M. J. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin. Infect. Dis. 61, 1835\u20131838 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"1152_CR5","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.vaccine.2008.11.098","volume":"27","author":"I Ridda","year":"2009","unstructured":"Ridda, I. et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 27, 1628\u20131636 (2009).","journal-title":"Vaccine"},{"key":"1152_CR6","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1128\/IAI.67.5.2327-2333.1999","volume":"67","author":"JO Kim","year":"1999","unstructured":"Kim, J. O. et al. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect. Immun. 67, 2327\u20132333 (1999).","journal-title":"Infect. Immun."},{"key":"1152_CR7","first-page":"51","volume":"3","author":"MA Westerink","year":"2012","unstructured":"Westerink, M. A., Schroeder, H. W. Jr. & Nahm, M. H. Immune responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Aging Dis. 3, 51\u201367 (2012).","journal-title":"Aging Dis."},{"key":"1152_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1128\/CVI.13.2.165-169.2006","volume":"13","author":"S Romero-Steiner","year":"2006","unstructured":"Romero-Steiner, S. et al. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin. Vaccin. Immunol. 13, 165\u2013169 (2006).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1152_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nri2494","volume":"9","author":"AJ Pollard","year":"2009","unstructured":"Pollard, A. J., Perrett, K. P. & Beverley, P. C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9, 213\u2013220 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1152_CR10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","volume":"372","author":"MJ Bonten","year":"2015","unstructured":"Bonten, M. J. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 372, 1114\u20131125 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1152_CR11","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/cid\/ciy312","volume":"67","author":"JM McLaughlin","year":"2018","unstructured":"McLaughlin, J. M. et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin. Infect. Dis. 67, 1498\u20131506 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"1152_CR12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/infdis\/jiab474","volume":"225","author":"JY Heo","year":"2022","unstructured":"Heo, J. Y. et al. Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults: a prospective, test-negative study. J. Infect. Dis. 225, 836\u2013845 (2022).","journal-title":"J. Infect. Dis."},{"key":"1152_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.trivac.2016.04.004","volume":"5","author":"SW Patterson","year":"2016","unstructured":"Patterson, S. W. et al. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials Vaccinol. 5, 92\u201396 (2016).","journal-title":"Trials Vaccinol."},{"key":"1152_CR14","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.vaccine.2018.01.049","volume":"36","author":"JA Suaya","year":"2018","unstructured":"Suaya, J. A. et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine 36, 1477\u20131483 (2018).","journal-title":"Vaccine"},{"key":"1152_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126543","volume":"44","author":"A Hsiao","year":"2025","unstructured":"Hsiao, A. et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults. Vaccine 44, 126543 (2025).","journal-title":"Vaccine"},{"key":"1152_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1128\/IAI.00768-10","volume":"79","author":"S Park","year":"2011","unstructured":"Park, S. & Nahm, M. H. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect. Immun. 79, 314\u2013320 (2011).","journal-title":"Infect. Immun."},{"key":"1152_CR17","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.1016\/j.vaccine.2008.07.071","volume":"26","author":"JG Schenkein","year":"2008","unstructured":"Schenkein, J. G., Park, S. & Nahm, M. H. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 26, 5521\u20135526 (2008).","journal-title":"Vaccine"},{"key":"1152_CR18","doi-asserted-by":"publisher","first-page":"e00004","DOI":"10.1128\/CVI.00004-17","volume":"24","author":"H Adler","year":"2017","unstructured":"Adler, H., Ferreira, D. M., Gordon, S. B. & Rylance, J. Pneumococcal capsular polysaccharide immunity in the elderly. Clin. Vaccin. Immunol. 24, e00004\u2013e00017 (2017).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1152_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/cid\/ciab990","volume":"75","author":"B Essink","year":"2022","unstructured":"Essink, B. et al. Pivotal Phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged >\/=18 Years. Clin. Infect. Dis. 75, 390\u2013398 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1152_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/cei.13605","volume":"205","author":"LMA Janssen","year":"2021","unstructured":"Janssen, L. M. A. et al. The clinical relevance of IgM and IgA anti-pneumococcal polysaccharide ELISA assays in patients with suspected antibody deficiency. Clin. Exp. Immunol. 205, 213\u2013221 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"1152_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.exger.2017.12.014","volume":"105","author":"M van der Heiden","year":"2018","unstructured":"van der Heiden, M. et al. Lower antibody functionality in middle-aged adults compared to adolescents after primary meningococcal vaccination: Role of IgM. Exp. Gerontol. 105, 101\u2013108 (2018).","journal-title":"Exp. Gerontol."},{"key":"1152_CR22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1128\/CVI.00248-12","volume":"19","author":"B Simell","year":"2012","unstructured":"Simell, B. et al. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine. Clin. Vaccin. Immunol. 19, 1618\u20131623 (2012).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1152_CR23","doi-asserted-by":"publisher","first-page":"e0195799","DOI":"10.1371\/journal.pone.0195799","volume":"13","author":"J Southern","year":"2018","unstructured":"Southern, J. et al. Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. PLoS One 13, e0195799 (2018).","journal-title":"PLoS One"},{"key":"1152_CR24","doi-asserted-by":"publisher","first-page":"e0194823","DOI":"10.1371\/journal.pone.0194823","volume":"13","author":"M Vissers","year":"2018","unstructured":"Vissers, M. et al. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in the Netherlands. PLoS One 13, e0194823 (2018).","journal-title":"PLoS One"},{"key":"1152_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12979-023-00391-3","volume":"20","author":"Y van Sleen","year":"2023","unstructured":"van Sleen, Y. et al. Frailty is related to serum inflammageing markers: results from the VITAL study. Immun. Ageing 20, 68 (2023).","journal-title":"Immun. Ageing"},{"key":"1152_CR26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.vaccine.2010.12.121","volume":"29","author":"B Simell","year":"2011","unstructured":"Simell, B. et al. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine 29, 1929\u20131934 (2011).","journal-title":"Vaccine"},{"key":"1152_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/infdis\/163.2.346","volume":"163","author":"HV Raff","year":"1991","unstructured":"Raff, H. V. et al. Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1. J. Infect. Dis. 163, 346\u2013354 (1991).","journal-title":"J. Infect. Dis."},{"key":"1152_CR28","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.4049\/jimmunol.148.6.1879","volume":"148","author":"SD Shyur","year":"1992","unstructured":"Shyur, S. D., Raff, H. V., Bohnsack, J. F., Kelsey, D. K. & Hill, H. R. Comparison of the opsonic and complement triggering activity of human monoclonal IgG1 and IgM antibody against group B streptococci. J. Immunol. 148, 1879\u20131884 (1992).","journal-title":"J. Immunol."},{"key":"1152_CR29","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3389\/fimmu.2017.00817","volume":"8","author":"M van der Heiden","year":"2017","unstructured":"van der Heiden, M. et al. Novel intervention in the aging population: a primary meningococcal vaccine inducing protective IgM responses in middle-aged adults. Front. Immunol. 8, 817 (2017).","journal-title":"Front. Immunol."},{"key":"1152_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10875-010-9501-7","volume":"31","author":"D Frasca","year":"2011","unstructured":"Frasca, D. & Blomberg, B. B. Aging affects human B cell responses. J. Clin. Immunol. 31, 430\u2013435 (2011).","journal-title":"J. Clin. Immunol."},{"key":"1152_CR31","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.4049\/jimmunol.175.5.3262","volume":"175","author":"Y Shi","year":"2005","unstructured":"Shi, Y. et al. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J. Immunol. 175, 3262\u20133267 (2005).","journal-title":"J. Immunol."},{"key":"1152_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/nyas.12823","volume":"1362","author":"V Martin","year":"2015","unstructured":"Martin, V., Wu, Y. C., Kipling, D. & Dunn-Walters, D. K. Age-related aspects of human IgM(+) B cell heterogeneity. Ann. N. Y Acad. Sci. 1362, 153\u2013163 (2015).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"1152_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13703","volume":"21","author":"A Cevirgel","year":"2022","unstructured":"Cevirgel, A. et al. Identification of aging-associated immunotypes and immune stability as indicators of post-vaccination immune activation. Aging Cell 21, e13703 (2022).","journal-title":"Aging Cell"},{"key":"1152_CR34","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.4049\/jimmunol.1600073","volume":"196","author":"NE Holodick","year":"2016","unstructured":"Holodick, N. E., Vizconde, T., Hopkins, T. J. & Rothstein, T. L. Age-related decline in natural IgM function: diversification and selection of the B-1a cell pool with age. J. Immunol. 196, 4348\u20134357 (2016).","journal-title":"J. Immunol."},{"key":"1152_CR35","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1084\/jem.188.12.2381","volume":"188","author":"M Boes","year":"1998","unstructured":"Boes, M., Prodeus, A. P., Schmidt, T., Carroll, M. C. & Chen, J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 188, 2381\u20132386 (1998).","journal-title":"J. Exp. Med."},{"key":"1152_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fimmu.2012.00066","volume":"3","author":"C Gronwall","year":"2012","unstructured":"Gronwall, C., Vas, J. & Silverman, G. J. Protective roles of natural IgM antibodies. Front. Immunol. 3, 66 (2012).","journal-title":"Front. Immunol."},{"key":"1152_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/clinids\/17.1.66","volume":"17","author":"DM Musher","year":"1993","unstructured":"Musher, D. M. et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin. Infect. Dis. 17, 66\u201373 (1993).","journal-title":"Clin. Infect. Dis."},{"key":"1152_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/clinids\/24.3.441","volume":"24","author":"DM Musher","year":"1997","unstructured":"Musher, D. M. et al. Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization. Clin. Infect. Dis. 24, 441\u2013446 (1997).","journal-title":"Clin. Infect. Dis."},{"key":"1152_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1086\/431524","volume":"192","author":"D Goldblatt","year":"2005","unstructured":"Goldblatt, D. et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J. Infect. Dis. 192, 387\u2013393 (2005).","journal-title":"J. Infect. Dis."},{"key":"1152_CR40","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1128\/CVI.00264-07","volume":"14","author":"P Balmer","year":"2007","unstructured":"Balmer, P. et al. Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine. Clin. Vaccin. Immunol. 14, 1442\u20131450 (2007).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1152_CR41","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fimmu.2019.00358","volume":"10","author":"E Ramos-Sevillano","year":"2019","unstructured":"Ramos-Sevillano, E., Ercoli, G. & Brown, J. S. Mechanisms of naturally acquired immunity to Streptococcus pneumoniae. Front. Immunol. 10, 358 (2019).","journal-title":"Front. Immunol."},{"key":"1152_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1086\/520200","volume":"29","author":"S Romero-Steiner","year":"1999","unstructured":"Romero-Steiner, S. et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29, 281\u2013288 (1999).","journal-title":"Clin. Infect. Dis."},{"key":"1152_CR43","first-page":"287","volume":"12","author":"BT Hu","year":"2005","unstructured":"Hu, B. T. et al. Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin. Diagn. Lab. Immunol. 12, 287\u2013295 (2005).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"1152_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/srep42137","volume":"7","author":"E van der Maten","year":"2017","unstructured":"van der Maten, E., de Jonge, M. I., de Groot, R., van der Flier, M. & Langereis, J. D. A versatile assay to determine bacterial and host factors contributing to opsonophagocytotic killing in hirudin-anticoagulated whole blood. Sci. Rep. 7, 42137 (2017).","journal-title":"Sci. Rep."},{"key":"1152_CR45","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/S0264-410X(03)00025-2","volume":"21","author":"LH Lee","year":"2003","unstructured":"Lee, L. H., Frasch, C. E., Falk, L. A., Klein, D. L. & Deal, C. D. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 21, 2190\u20132196 (2003).","journal-title":"Vaccine"},{"key":"1152_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-3083.1994.tb03416.x","volume":"39","author":"A Aase","year":"1994","unstructured":"Aase, A. & Michaelsen, T. E. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand. J. Immunol. 39, 581\u2013587 (1994).","journal-title":"Scand. J. Immunol."},{"key":"1152_CR47","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1128\/IAI.67.9.4935-4938.1999","volume":"67","author":"KR Lottenbach","year":"1999","unstructured":"Lottenbach, K. R. et al. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect. Immun. 67, 4935\u20134938 (1999).","journal-title":"Infect. Immun."},{"key":"1152_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1046\/j.1365-2249.1999.01077.x","volume":"118","author":"M Anttila","year":"1999","unstructured":"Anttila, M., Voutilainen, M., Jantti, V., Eskola, J. & Kayhty, H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118, 402\u2013407 (1999).","journal-title":"Clin. Exp. Immunol."},{"key":"1152_CR49","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/infdis\/162.2.482","volume":"162","author":"E Bardardottir","year":"1990","unstructured":"Bardardottir, E., Jonsson, S., Jonsdottir, I., Sigfusson, A. & Valdimarsson, H. IgG subclass response and opsonization of Streptococcus pneumoniae after vaccination of healthy adults. J. Infect. Dis. 162, 482\u2013488 (1990).","journal-title":"J. Infect. Dis."},{"key":"1152_CR50","doi-asserted-by":"publisher","first-page":"929483","DOI":"10.3389\/fcimb.2022.929483","volume":"12","author":"E Gil","year":"2022","unstructured":"Gil, E., Noursadeghi, M. & Brown, J. S. Streptococcus pneumoniae interactions with the complement system. Front. Cell Infect. Microbiol. 12, 929483 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1152_CR51","doi-asserted-by":"publisher","first-page":"10676","DOI":"10.18632\/aging.103286","volume":"12","author":"W Cao","year":"2020","unstructured":"Cao, W. et al. Modelling biological age based on plasma peptides in Han Chinese adults. Aging 12, 10676\u201310686 (2020).","journal-title":"Aging"},{"key":"1152_CR52","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","volume":"9","author":"M Gaya da Costa","year":"2018","unstructured":"Gaya da Costa, M. et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. Front. Immunol. 9, 2664 (2018).","journal-title":"Front. Immunol."},{"key":"1152_CR53","doi-asserted-by":"crossref","unstructured":"MacIntyre, C. R. et al. Frailty and immune response to pneumococcal vaccines among the elderly hospitalised patients. Int. J. Infect. Dis. 12 (2008).","DOI":"10.1016\/j.ijid.2008.05.355"},{"key":"1152_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41590-023-01717-5","volume":"25","author":"S Ravichandran","year":"2024","unstructured":"Ravichandran, S. et al. Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults. Nat. Immunol. 25, 316\u2013329 (2024).","journal-title":"Nat. Immunol."},{"key":"1152_CR55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/vaccines7010004","volume":"7","author":"E Linley","year":"2019","unstructured":"Linley, E., Bell, A., Gritzfeld, J. F. & Borrow, R. Should Pneumococcal Serotype 3 be included in serotype-specific immunoassays?. Vaccines 7, 4 (2019).","journal-title":"Vaccines"},{"key":"1152_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50760-9","volume":"15","author":"M van der Heiden","year":"2024","unstructured":"van der Heiden, M. et al. Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial. Nat. Commun. 15, 6603 (2024).","journal-title":"Nat. Commun."},{"key":"1152_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101734","volume":"5","author":"A Hendriks","year":"2024","unstructured":"Hendriks, A. et al. Glycan-specific IgM is critical for human immunity to Staphylococcus aureus. Cell Rep. Med. 5, 101734 (2024).","journal-title":"Cell Rep. Med."},{"key":"1152_CR58","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1016\/j.vaccine.2016.04.093","volume":"34","author":"RW Frenck Jr.","year":"2016","unstructured":"Frenck, R. W. Jr. et al. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine 34, 3454\u20133462 (2016).","journal-title":"Vaccine"},{"key":"1152_CR59","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1016\/j.vaccine.2020.07.005","volume":"38","author":"D Van Baarle","year":"2020","unstructured":"Van Baarle, D. et al. Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project. Vaccine 38, 5896\u20135904 (2020).","journal-title":"Vaccine"},{"key":"1152_CR60","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","volume":"29","author":"D Cooper","year":"2011","unstructured":"Cooper, D. et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 29, 7207\u20137211 (2011).","journal-title":"Vaccine"},{"key":"1152_CR61","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1128\/CVI.00408-09","volume":"17","author":"KE Elberse","year":"2010","unstructured":"Elberse, K. E., Tcherniaeva, I., Berbers, G. A. & Schouls, L. M. Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. Clin. Vaccin. Immunol. 17, 674\u2013682 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1152_CR62","doi-asserted-by":"publisher","first-page":"e00400","DOI":"10.1128\/mSphere.00400-19","volume":"4","author":"S Jones","year":"2019","unstructured":"Jones, S. et al. Assignment of Serotype-Specific IgG1, IgG2, and IgA weight-based antibody units to the human pneumococcal standard reference serum, 007sp. mSphere 4, e00400\u2013e00419 (2019).","journal-title":"mSphere"},{"key":"1152_CR63","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/cdli.2.5.590-597.1995","volume":"2","author":"SA Quataert","year":"1995","unstructured":"Quataert, S. A. et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2, 590\u2013597 (1995).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"1152_CR64","first-page":"1064","volume":"11","author":"SA Quataert","year":"2004","unstructured":"Quataert, S. A. et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). Clin. Diagn. Lab. Immunol. 11, 1064\u20131069 (2004).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"1152_CR65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.32614\/RJ-2012-014","volume":"4","author":"JD Kloke","year":"2012","unstructured":"Kloke, J. D. & McKean, J. W. Rfit: Rank-based estimation for linear models. R. J. 4, 57\u201364 (2012).","journal-title":"R. J."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01152-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01152-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01152-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:13:16Z","timestamp":1747210396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01152-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1152"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01152-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W.P. is an employee of Pfizer Inc. S.P.L. is a former employee of Pfizer Inc. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}